You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

TORONTO, Jan. 7, 2021 /PRNewswire/ - Emerging psychedelic drug development company Diamond Therapeutics has received new investment from the Ontario Brain Institute (OBI),a not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. An early believer in Diamond's precision, low-dose approach to psychedelic therapies, OBI provided the company with funding in 2019. Now, OBI has more than doubled its investment. Proceeds will support a clinical trial of low-dose psilocybin intended to begin in early 2021, pending Health Canada approval. The investment is in the form of a convertible debenture. "There's an unmet need for the next generation of drugs in the mental health space," says Tom Mikkelsen, President & Scientific Director of OBI. "By furthering our investment in Diamond through the NERD (Neurotech Early Research & Development) program, OBI will help improve the evidence base related to low-dose psilocybin. We hope this investment will lead to more accessible treatment options for people living with anxiety and other mental health disorders," he adds. "We are very grateful for this follow-on support," says Judith Blumstock, CEO and Founder of Diamond. "Initial funding from OBI subsidized compelling foundational research into precision, low-dose therapies, and OBI's continued support will help advance our work to the next level." OBI's first backing helped fund several animal studies exploring the behavioural effects of low-dose psilocybin. Data from Diamond's early research rallied investors to an oversubscribed $2.8 million seed round in spring 2020. Following its planned Phase 1 clinical trial of low-dose psilocybin in 2021, Diamond intends to conduct clinical studies in anxiety disorders, which represent the most prevalent form of mental illness. "OBI's backing will further our pursuit of accessible, low-dose, non-hallucinogenic therapies," says Blumstock. "We are working to deliver solutions that are safer and more effective, and can provide patients with an ideal therapeutic for the conditions affecting their mental health." About DiamondDiamond Therapeutics is a psychedelic drug development company based in Toronto. Our mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. Diamond's focus is developing and commercializing sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort maximizing the positive impact better drugs can have on the global mental health crisis. To learn more about Diamond, visit us at www.diamondthera.com. About Ontario Brain InstituteThe Ontario Brain Institute is a not-for-profit organization that accelerates discovery and innovation, benefiting both patients and the economy. Our collaborative 'team science' approach promotes brain research, commercialization and care by connecting researchers, clinicians, industry, patients, and their advocates to improve the lives of those living with brain disorders. Welcome to Brain Central. Visitwww.braininstitute.cafor more information. Follow us on Twitter (@OntarioBrain).Funding provided, in part, by the Government of Ontario. SOURCE Diamond Therapeutics Inc.

Answer: Ontario Brain Institute Increases Investment in Diamond Therapeutics to Accelerate Innovation in Mental Health